Immatics NV (IMTX) Stock Forecast & Price Target

Immatics is viewed favorably because its dual-modality PRAME platform combines a potentially first-in-class autologous cell therapy, anzu-cel, with an off-the-shelf bispecific, IMA402, giving it two shots on goal in melanoma and beyond. The company’s lead Phase 3 program is underpinned by encouraging Phase 1 data, a manageable safety profile, and practical advantages versus approved TIL therapy, including faster manufacturing, shorter lymphodepletion, and outpatient-friendly dosing, while cash of about $522 million and an additional $150 million raised in August 2026 support operations into 2028. Early IMA402 activity, including 30% cORR across indications and 29% in melanoma, alongside broad PRAME expression in target tumors and multiple 2026 catalysts, strengthens confidence that Immatics can expand from melanoma into additional solid-tumor markets.

Immatics is a clinical-stage biotechnology company whose outlook is weakened by high execution risk across data, safety, regulatory, and commercialization milestones, including slower-than-expected event accrual in SUPRAME and FDA-driven amendments that pushed final PFS data to 1H27 with BLA submission following in 2027. Its lead programs still face unresolved questions around leukapheresis bottlenecks, potential toxicity, and whether early clinical activity will translate into durable tumor regression or approval-quality evidence. In addition, limited precedent in TCR-T therapies, intense competition from Iovance Biotherapeutics and private Immunocore, intellectual property uncertainty, and the need for additional capital before profitability increase the risk of dilution and downward revisions to fundamentals.